GSK plc recently announced it will start Phase III trials of a low carbon version of its metered dose inhaler (MDI), Ventolin (salbutamol), using a next generation propellant, in 2024. If successful, it has the potential to reduce greenhouse gas emissions from use of the inhaler by approximately 90%, significantly contributing to GSK’s ambitious net-zero climate targets. Thirty-five million patients with respiratory conditions around the world rely on this inhaler as their rescue medication. However, it accounts for close to half (49%) of GSK’s carbon footprint, as well as contributing…
Read MoreGSK announces major step towards sustainability ambitions with advancement of low carbon Ventolin programme to Phase III trials
